Business Context and Reporting Period
This Form 8-K was filed by NantKwest, Inc. (NK) on August 21, 2020, reporting the entry into a Material Definitive Agreement with ImmunityBio, Inc. The filing details a strategic collaboration to jointly develop, manufacture, and market therapeutics and vaccines targeting SARS-CoV-2 and COVID-19.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the terms of the new collaboration agreement.
Material Changes and Agreement Terms
- Agreement Scope: The parties agreed to jointly develop ceNK, haNK, mesenchymal stem cells (MSC), adenovirus constructs (Ad5), and N-803 (a novel IL-15 cytokine superagonist).
- Product Roles: Ad5 will be developed as a vaccine, while ceNK, haNK, MSC, and N-803 will be developed as therapeutics for various stages of infection.
- Contributions: NantKwest contributes ceNK, haNK, MSC, and manufacturing capabilities. ImmunityBio contributes Ad5 and N-803.
- Cost Sharing: All costs relating to global development and manufacturing will be shared equally.
- Profit Sharing: Global net profits from individual products are shared 60% to the contributing party and 40% to the other. Profits from combined collaboration products are shared equally.
- Responsibilities: NantKwest is primarily responsible for manufacturing (except N-803). Each party handles regulatory affairs and commercialization for its own contributed products.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or quantitative outlook projections. Management commentary is limited to the strategic intent of the collaboration. The agreement supersedes a binding term sheet executed on May 22, 2020. A joint steering committee with equal representation from both parties will supervise the collaboration. The full text of the agreement is incorporated by reference in the upcoming Form 10-Q for the period ended September 30, 2020.
Investor Verification Checklist
- Verify the specific terms of the Collaboration Agreement in the upcoming Form 10-Q exhibit.
- Confirm the regulatory status and development timelines for the five product candidates (ceNK, haNK, MSC, Ad5, N-803).
- Assess the financial impact of the 50/50 cost-sharing arrangement on NantKwest's cash burn rate.
- Review the definition of "net profits" and the specific circumstances under which the 60/40 profit split may be adjusted.